Rankings
▼
Calendar
URGN Q3 2025 Earnings — UroGen Pharma Ltd. Revenue & Financial Results | Market Cap Arena
URGN
UroGen Pharma Ltd.
$927M
Q3 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$27M
+9.0% YoY
Gross Profit
$24M
88.1% margin
Operating Income
-$27M
-99.7% margin
Net Income
-$33M
-121.3% margin
EPS (Diluted)
$-0.69
QoQ Revenue Growth
+13.5%
Cash Flow
Operating Cash Flow
-$42M
Free Cash Flow
-$42M
Stock-Based Comp.
$3M
Balance Sheet
Total Assets
$185M
Total Liabilities
$300M
Stockholders' Equity
-$115M
Cash & Equivalents
$90M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$27M
$25M
+9.0%
Gross Profit
$24M
$23M
+6.4%
Operating Income
-$27M
-$18M
-56.1%
Net Income
-$33M
-$24M
-40.9%
Revenue Segments
Jelmyto
$26M
100%
← FY 2025
All Quarters
Q4 2025 →